{rfName}
Su

Indexed in

License and use

Citations

Altmetrics

Grant support

Funded by THERIVA BIOLOGICS (formerly VCN Biosciences). Durvalumab was provided by AstraZeneca.

Impact on the Sustainable Development Goals (SDGs)

Analysis of institutional authors

Jove, MAuthorMoreno, RAuthorAlemany, RAuthorCapella, GAuthor

Share

November 21, 2024
Publications
>
Meeting Abstract
Bronze

Survival outcomes in phase I trial combining VCN-01 and durvalumab (MEDI4736) in subjects with recurrent/ metastatic head and neck squamous cell carcinoma refractory to previous immunotherapy treatment

Publicated to:Annals Of Oncology. 34 S589-S590 - 2023-10-01 34(), DOI: 10.1016/j.annonc.2023.09.2081

Authors: Jové, M; Braña, I; Bernal, MO; Calvo, AH; Lecuona, CE; Pastrana, JDA; Mato-Berciano, A; Maliandi, MV; Torres-Manjon, S; Moreno, R; Le, C; Nuciforo, PG; Alemany, R; Capella, G; Blasco, C; Piqueras, MC; Nin, RM

Affiliations

- Author
Catalan Inst Oncol ICO, Med Oncol Phase Funct Unit 1 - Author
ICO Inst Catala Oncol Hosp Duran I Reynals, IDIBELL, ProCure Program ICO Program Mol Mech & Expt Ther - Author
IDIBELL, Program Mol Mech & Expt Therapy Oncol Oncobell - Author
IGTP, ICO Inst Catala Oncol, Med Oncol Dept, B ARGO Grp - Author
Theriva Biol, Clin Operat - Author
Theriva Biol, R&D - Author
Theriva Biol, Stat & Analyt - Author
Vall dHebron Inst Oncol VHIO - Author
Vall dHebron Inst Oncol VHIO Cellex Ctr, Mol Oncol Dept - Author
See more

Abstract

Keywords

Good health and well-being

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Annals Of Oncology due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2023, it was in position 4/322, thus managing to position itself as a Q1 (Primer Cuartil), in the category Oncology. Notably, the journal is positioned above the 90th percentile.

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-07-26:

  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 4 (PlumX).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.
Continuing with the social impact of the work, it is important to emphasize that, due to its content, it can be assigned to the area of interest of ODS 3 - Good Health and Well-Being, with a probability of 84% according to the mBERT algorithm developed by Aurora University.

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: United States of America.

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (JOVE CASULLERAS, MARIA) and Last Author (Nin, RM).